Montana Becomes a Pioneer for Experimental AI Applications in Medicine

As MIT Technology Review reports (https://www.technologyreview.com/2026/07/31/1140999/the-download-montanas-right-to-try-law-anthropic-hacks/), the US state of Montana has taken a significant step to establish itself as a center for experimental medical applications—especially in the field of Artificial Intelligence (AI). The new regulations allow biotech companies that have already developed AI-supported therapies and diagnostic methods in early testing phases to trial them faster and more flexibly on the market. This could significantly accelerate the development of innovative treatment options.

New Framework Conditions for AI in Medicine

Montana’s legislation enables companies that have already tested AI-supported drugs or diagnostic systems in initial studies—sometimes with only ten subjects—to make these available to patients under controlled conditions. This addresses a previous bottleneck in medical research: the often lengthy and costly approval procedures that delay innovative technologies. The regulation is part of a broader trend in which AI is increasingly used as a tool in medicine—from analyzing large data sets to personalized therapy development to automated diagnostics. Montana thus positions itself as a pioneer offering experimental innovations a legal framework that ensures both safety and flexibility.

Why It Matters

The accelerated testing of AI applications in medicine could significantly advance the development of new therapies. Especially for rare or hard-to-treat diseases, AI-supported approaches offer new opportunities, as they can recognize patterns and suggest personalized treatment paths that are difficult for human researchers to access alone. Moreover, Montana’s model could inspire other states and countries to create similar regulations that promote both innovation and patient welfare. Balancing rapid availability and safety remains a central challenge.

Challenges and Outlook

Critics warn that too rapid approval of experimental AI applications can carry risks, such as insufficiently tested algorithms or lack of long-term data. Therefore, Montana’s legislation includes strict requirements and monitoring mechanisms to ensure patient safety. In the long term, the combination of regulatory flexibility and technological progress could revolutionize medical research. AI systems are becoming increasingly powerful, and their integration into clinical workflows could make healthcare more efficient and individualized.

Conclusion

Montana’s new approach demonstrates how regulatory innovations can promote the development of AI in medicine. By providing experimental technologies with a legal framework that allows rapid testing and application, a model emerges that holds both opportunities and challenges for the future of medicine. For patients, researchers, and companies, this offers a new perspective that could pave the way for groundbreaking medical innovations.